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Abstract  
 
Drug bioavailability may vary greatly amongst individuals, affecting both efficacy and toxicity: in humans, genetic 
variations account for a relevant proportion of such variability. In the last decade the use of pharmacogenetics in clinical 
practice, as a tool to individualize treatment, has shown a different degree of diffusion in various clinical fields.  
In the field of infectious diseases, several studies identified a great number of associations between host genetic 
polymorphisms and responses to antiretroviral therapy. For example, in patients treated with abacavir the screening for 
HLA-B*5701 before starting treatment is routine clinical practice and standard of care for all patients; efavirenz plasma 
levels is influenced by single nucleotide polymorphism (SNP) CYP2B6-516G>T (rs3745274). Regarding antibiotics, 
many studies investigated drug transporters involved in antibiotic bioavailability, especially for fluoroquinolones, 
cephalosporins, and antituberculars. To date, few data are available about pharmacogenetics of recently developed 
antibiotics such as tigecycline, daptomycin or linezolid. Considering the effect of SNPs in gene coding for proteins 
involved in antibiotics bioavailability, few data have been published.  
Increasing knowledge in the field of antibiotic pharmacogenetics could be useful to explain the high drug inter-patients 
variability and to individualize therapy. In this paper we reported an overview of pharmacokinetics, pharmacodynamics, 
and pharmacogenetics of antibiotics to underline the importance of an integrated approach in choosing the right dosage 
in clinical practice.  
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Introduction 
Pharmacogenetics (PG), known as the study of inter-individual variation in DNA sequences related to 
pharmacokinetics/pharmacodynamics (PK/PD) of drugs,  has rapidly evolved over the past decade and is increasingly 
recognized as a discipline with great potential for individualization, especially in critical care patients [1]. Important 
applications of PG include the identification of genetic mechanisms that may influence drugs exposure, toxicity and/or 
response to treatments [2]. Individual PK variability can also play a role in treatment failure, either directly through sub-
therapeutic drug levels, or indirectly when toxic drug levels are associated with side effects.  
PK variability of antibiotics depends on several factors, among which the most important are: 
Drug–drug interactions: There are plenty of interactions involving antibiotic agents [3]. The more common interaction 
depends on co-administration of antibiotic with compounds that induce or inhibit the activity of metabolizing enzymes 
as cytochrome P450 (CYP P450) system or transporters such as P-glycoprotein (P-gp).  
Drug–food interactions: Interactions between food and oral drugs can unintentionally reduce or increase the absorption 
and, indirectly, the effect of drug, resulting in therapeutic failure or increased toxicity. The majority of clinically 
relevant food-drug interactions are caused by food-induced changes in bioavailability of drug. For example, 
ciprofloxacin [4], doxicycline [5], norfloxacin [6] oral absorption is reduced if administered with milk and the clinical 
effect observed is treatment failure.  
Sex: Most reports of sex differences involve oral administration of low bioavailable drugs that undergo cytochrome 3A4 
(CYP3A4) metabolism and P-gp transport. For example, greater inhibition of clarithromycin on intestinal metabolism 
was observed in women than in men [7]. Moreover body mass index and volume of distribution of drugs were 
influenced by sex. 
Disease state (i.e. renal and hepatic function): Renal or hepatic impairment is associated with lower excretion of drugs 
that are excreted via these two ways. Accumulation of drugs in these compartments is often correlated with emergence 
of toxicity. For example meropenem, vancomycin, and daptomycin are mainly excreted through the kidneys and 
therefore a dosage adjustment is required for patients with renal impairment [8]. 
 
The hypothesis that genetic differences could play a role in influencing a patient’s response was supported by reports 
showing that patients from distinct ethnic groups have significantly different clinical response [9, 10]. Genetic 
variability in drug metabolizing enzymes or drug transporters across ethnic groups, probably explains some of the 
differences between populations, although other factors such as body weight may also contribute. It should also be 
considered that while initial plasma concentrations may be unaffected by genetics, the inducibility of drug metabolizing 
enzymes by rifampicin or other co-administered drugs may vary according to the various polymorphisms affecting gene 
regulation such as promoter variation or nuclear factor.  
In the last decade, PG has been used in clinical practice to individualize treatment. In some areas, such as in 
cardiovascular diseases or in cancer, PG testing is already applied for selecting or dosing a specific medication, while in 
other fields, such as in psychiatry, the PG approach has been mostly used for the identification, validation and 
development of new biomarkers.  
In the last years several single nucleotide polymorphisms (SNPs) that alter the expression of drug transporters proteins 
or metabolizing enzymes were found to influence drug PK. To date, SNPs in several genes coding for such proteins are 
known: 
Multi-drug transporter genes.  Drug transporters can be generally divided into two major classes: uptake and efflux 
transporters. Uptake transporters act by facilitating the translocation of drugs into cells or compartments. Efflux 
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transporters act by exporting drugs from the intracellular to the extracellular compartment. For example, amongst 
uptake transporters, the organic anion transporting polypeptide 1B1 (OATP1B1), which plays a major role in the 
hepatic uptake of drugs, is coded by a polymorphic gene. The aplotype OATP1B1*15 was found to be related with high 
plasma levels of pravastatin in Caucasians  [11, 12]. The genetically polymorphic transporter P-gp or MDR1 is a well-
known efflux transporter with ubiquitary expression coded in humans by ABCB1 gene. The most famous SNP is 
3435C>T (rs1045642). It was observed that subjects with 3435C>T mutation have higher levels of mutated P-gp in the 
duodenum and higher plasma area under the curve (AUC) of orally-administered digoxin than subjects with the wild 
type allele [13]. Many clinical studies investigated the influence of SNPs on ABCB1 to clarify the clinical impact on the 
PK and PDs of various substrate drugs because of the relatively high frequency of this mutation and ethnic differences 
in the frequency (about 10% in African-Americans, 40–50% in Caucasians and Asians) [14].  
Another genetically polymorphic efflux transporter is the breast cancer resistance protein (BCRP) coded by ABCG 
gene. The most important SNP is 421C>A (rs2231142). Since its frequency is relatively high, several clinical studies on 
this SNP have been carried out. 421C>A in BCRP gene was reported to cause the increase in the plasma concentrations 
of rosuvastatin and diflomotecan [15, 16]. Moreover, 24C>T (rs717620) mutation in the gene coding for the multidrug 
resistance–associated protein 2 (MRP2) caused the increase in the steady-state plasma trough concentration of 
mycophenolic acid in transplanted patients [17] and the increase in the plasma AUC of methotrexate [18]. 
Cytochrome P450 metabolizing enzymes:  
To date, it is well established that the SNP 516C>T (rs3745274) in gene coding for CYP2B6 is associated with 
significantly greater efavirenz plasma exposure during HIV therapy [19, 20]. Among antifungals, voriconazole is 
extensively metabolized by the cytochrome P450 system and CYP2C19 is involved in the primary route of elimination. 
Several studies reported that SNPs in CYP2C19 coding gene are associated to voriconazole plasma levels in adult 
patients [21] and children [22].  
The study of the association between drug plasma levels and SNPs in gene coding for protein involved in antibiotics 
absorption, distribution, metabolism, and elimination (ADME) processes may be useful to choose the right dosage 
especially at the beginning of treatment. We present a comprehensive review of the published literature to summarize 
the state of the art of PG and PK of antibiotics. 
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Aminoglycosides  
Aminoglycosides (AGAs) have been extensively used; streptomycin was the first aminoglycosides discovered and was 
isolated in 1943 from Streptomyces griseus. A second generation of AGAs, such as dibekacin (1971), amikacin (1972), 
arbekacin (1973), isepamicin (1975), and netilmicin (1976) were developed during the past decades [23].  
Despite their nephrotoxicity and ototoxicity, AGAs are valuable in current clinical practice, since they retain good 
activity also against multidrug-resistant gram-negative pathogens, such as Pseudomonas aeruginosa and Acinetobacter 
spp.  
Mechanism of action. Aminoglycosides act mostly as protein synthesis inhibitors, although their exact mechanism of 
action is not fully known: they interfere with the proofreading process, causing increased rate of error in synthesis with 
premature termination. Also, there is evidence of inhibition of ribosomal translocation where the peptidyl-tRNA moves 
from the A-site to the P-site. They can also disrupt the integrity of bacterial cell membrane.  
PK-PD parameters predictive of efficacy. Time-kill studies have shown a concentration-dependent and partially 
concentration-dependent bacterial killing against gram-negative and gram-positive bacteria, respectively. PD data show 
that the administration by an extended-interval dosing scheme greatly enhances the potential of these agents, with the 
goal of achieving an AUC
 
of 100 mg*h/L and a Cmax/MIC ratio of 8–10. Aminoglycosides are characterized by a 
significant variability in the relationship between the dose administered and the resultant plasma levels in blood and 
therapeutic drug monitoring (TDM) is frequently necessary to obtain the correct dose.  
ADME. Aminoglycosides can only be administered parenterally, except for intestinal infections or indication for 
decontamination. Protein binding is weak (0 to 30%) and the apparent elimination half-life is approximately 2h. 
Volume of distribution is low (<0.3 L/kg) thus aminoglycosides are mainly distributed in blood plasma. The major 
route of aminoglycosides elimination is renal excretion as only a small fraction was found to be eliminated through the 
bile (0.5-2% of the administered dose). The biotransformation is negligible (<10%); they are found almost entirely in 
the unchanged, biologically active form in the urine. The PK of elimination is independent of the dose and route of 
administration. Tissue diffusion is poor, but there is a good diffusion into peritoneal, pleural and pericardial  fluid and 
synovial effusions, where the concentration attains 25 to 50% of levels in serum; the renal accumulation occurs 
particularly in the cortex [24].   
PG data. To date, only one study was published about PG of aminoglycosides (Table 1). Oral absorption of some drugs 
is inhibited by P-gp which is involved in drug efflux in the brush border of intestinal mucosa. Banerjee et al. [25] found 
that P-gp is involved in tobramycin efflux. Therefore, P-gp inhibitors may have potential role to transport 
aminoglycosides, through gut, which is otherwise poorly absorbed after oral administration.  
Tetracyclines  
Tetracyclines, represent a large group of antibacterials, some of which were first introduced into clinical practice in the 
1950s (tetracycline) while others have recently been approved (the glycylcycline, tigecycline). The microbial spectrum 
includes gram-positive and gram-negative bacteria, intracellular Chlamydiae, Mycoplasma, Rickettsiae and several 
parasites such as malaria [26].  
Mechanism of action. Tetracyclines are generally bacteriostatic. They reversibly bind to the 16S  part of 
the 30S ribosomal subunit.  
PK-PD parameters predictive of efficacy. Tetracyclines exhibit a predominantly time-dependent killing activity with 
a prolonged post-antibiotic effect. The PK parameter predictive of efficacy in these compounds is the AUC related to 
MIC (AUC/MIC). A target PK/PD breakpoint has still not been clearly identified.  
6 
 
ADME. Tetracycline is only available as a oral formulation, while doxycicline and minocycline can be given either 
orally or intravenously (iv not in Italy). The reported tissue distribution varies depending primarily upon the 
liphophilicity of the individual drugs. Protein binding is modest from 20% to 60%.  
Oral absorption of tetracyclines occurs in the stomach and proximal small intestine. Oral bioavailability of these 
compounds is relatively high, ranging from 75% to 100%. Food can reduce the absorption of both tetracycline and 
doxycycline up to 50% [27]. Half-life of tetracyclines is relatively long, from 8 to 25 hours. These compounds are 
eliminated by both hepatic and renal mechanisms, they are filtered by the glomerulus but primarily reabsorbed because 
of their high lipid solubility. Tetracycline class are not effectively dialyzed, thus dose adjustment is not necessary in 
patients with renal impairment.  
PG data. It was reported that minocycline exhibits anti-neurodegenerative properties [28-30] and that it is distributed to 
brain when administered by oral route [31]. Milane et al. investigated the interaction between riluzole, mynocycline and 
P-gp at the blood-brain barrier (BBB). They found that mynocycline and riluzole are both substrate of P-gp and that 
mynocycline is also inhibitor of P-gp and increases the brain diffusion of riluzole. Therefore the study confirmed that 
mynocycline and riluzole are transported by P-gp at the BBB level and that minocycline is involved in riluzole 
disposition into the brain trough P-gp [32] (Table 1).  
 
Other antibiotics Transporter Coding gene in-vitro 
model 
ADME process 
involved Reference 
Aminoglycosides 
     
Tobramycin P-pg ABCB1 Mice Oral delivery Banerjee et al. 2000 [25] 
  
 
   
Tetracyclines 
 
 
   
Minocycline P-pg ABCB1 Mice BBB transport Milane et al. 2007 [32] 
Riluzole 
     
Macrolides 
     
Azithromycin P-pg ABCB1 Rats 
Biliary and intestinal 
excretion Sugie et al. 2004 [33] 
Azytromycin OATP1A5 SLCO1A5 MDCKII 
cells and rats Intestinal absorption Garver et al. 2008 [34] Claritromycin 
     
Daptomycin P-pg ABCB1 
MDCKII 
cells and 
THP-1 
macrophages 
Intracellular activity 
against phagocytized S. 
Aureous 
Lemaire et al. 2007 [35] 
      
Rifampicin P-pg ABCB1 Mice Intracellular 
accumulation Schiuetz et al. 1996 [36] 
 
 
Table 1. Specific transporters of aminoglycosides, tetracyclines, macrolides, daptomycin, rifampicin and type of 
ADME processes involved. ADME, absorption distribution metabolism elimination; P-gp, P-glycoprotein; OAT, 
organic anion transporter; ABC, ATP binding cassette; SLC, solute carrier; BBB, blood brain barrier. 
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Tigecycline 
Tigecycline is an injectable antibacterial agent  classified as a glycylcycline. It is the first member of this class that has 
been specifically developed to overcome the two major mechanisms of tetracycline resistance, ribosomal protection and 
efflux. In vitro, tigecycline is active against a wide range of gram-positive and gram-negative aerobic and anaerobic 
bacteria.  
Mechanism of action. Tigecycline acts through inhibition of the bacterial protein translation by binding to the 30S 
ribosomal subunit and blocking the entry of amino-acyl tRNA molecules into the A site of the ribosome [37].  
PK-PD parameters predictive of efficacy. Tigecycline exhibits time-dependent bactericidal activity not only against 
Streptococcus pneumoniae, but also against Haemophilus influenzae and Neisseria gonorrhoeae [38]. The AUC/MIC 
ratio is considered the most predictive index related to the clinical and microbiological efficacy [39]. To date no 
efficacy and toxicity breakpoints have been identified.  
ADME. Tigecycline is available as a parenteral agent due to its limited oral bioavailability and it is administered i.v. as 
a 30-minute to 1h infusion, twice daily. Tigecycline has a large volume of distribution (7-10 L/kg) thus it is widely 
distributed in the body, with an half-life of 42 hours [39]. Tigecycline is moderately bound to human plasma proteins 
(71-89%) and it is eliminated by the liver via biliary excretion as unchanged drug and glucuronidation. Renal clearance 
is only a minor excretory way for tigecycline (approximately 10-15% of total systemic clearance) with less than 22% 
excreted unchanged in the urine. Tigecycline penetrates well into tissues and body fluids reaching higher concentrations 
compared to serum levels [40]. PK of tigecycline is not altered in patients with severe renal impairment as well as in 
patients with mild hepatic impairment. Therefore no dosage adjustment is required in these type of patients [39].  
PG data. Eukaryotic efflux transporters can modulate the cellular concentration and the intracellular activity of 
antibiotics. Thus, Lemaire et al. investigated the role of P-gp and MRP1 in the modulation of the cellular accumulation 
and activity of tigecycline. In contrast with other antibiotics, where accumulation and intracellular activity are reduced 
by P-pg, tigecycline was found to be substrate of neither P-pg or MRP1 efflux transporters [41].  
 
 
Macrolides 
Macrolides, such as erythromycin, oleandomycin, spiramycin, roxithromycin, josamycin, midecamycin, clarithromycin, 
azithromycin and dirithromycin, are active against gram-positive staphylococci such as Staphylococcus aureus, 
coagulates-negative staphylococci, β-hemolytic streptococci, other streptococci species and some enterococci. 
Additional activity has been documented, especially for some agents, against Haemophilus influenzae, some pathogenic 
Neisseria species, Bordetella, Corynebacterium, Chlamydia, Mycoplasma, Rickettsia and Legionella species [42]. 
Azithromycin is considered one of the first choices to treat patients with peptic ulcer to eradicate Helicobacter pylori 
together with other antibacterial agents, such as amoxicillin and metronidazole. 
Mechanism of action. Macrolides act by reversibly binding to the 23S ribosomal RNA (rRNA) in the 50S subunit of 
susceptible organisms, and inhibiting mRNA-directed protein synthesis. Moreover, they stimulate the dissociation of 
peptidyl-tRNA during translocation, suppressing RNA-dependent protein synthesis and inhibiting bacterial growth. 
Resistance to macrolides in clinical isolates is most frequently due to post-transcriptional methylation of a adenine 
residue of 23S ribosomal RNA, which leads to co-resistance to macrolides, lincosamides and streptogramins type B (the 
so-called MLSB phenotype) [43].  
PK-PD parameters predictive of efficacy. Macrolides are generally bacteriostatic. Bactericidal activity may occur 
under certain conditions or against specific microorganisms. Macrolides are different from the other classes of 
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antibacterial agents since they do not fall in a single category. T>MIC is, indeed, the most important parameter for 
erythromycin. Optimal efficacy is obtained when T>MIC is greater than 40% of the dosing interval [44]. 
However, experimental studies show that both T>MIC and AUC/MIC influence the clinical efficacy of clarithromycin 
and azithromycin. For azythromycin AUC/MIC appears to be the most important parameter with the ratio exceeding 25 
for optimal efficacy [43].  
ADME. Macrolides tend to be characterized by high bioavailability. After oral administration they are readily absorbed 
from the gastro intestinal tract if not inactivated by gastric acid. They are characterized by a high volume of distribution 
(1–2.5 L/kg) that reflects the extensive tissue penetration. 
They actually accumulate within many cells, including macrophages, in which they may be ≥20 times the plasma 
concentration. Macrolides tend to concentrate in the spleen, liver, kidneys, and particularly the lungs. They enter pleural 
and peritoneal fluids but not the cerebrospinal fluid (only 2–13% of plasma concentration unless the meninges are 
inflamed). They concentrate in the bile and milk. Up to 75% of the dose is bound to plasma proteins. Metabolic 
inactivation of the macrolides is usually extensive, but the relative proportion depends on the route of administration 
and the particular antibiotic. After oral administration, 80% of an erythromycin dose undergoes metabolic inactivation, 
whereas tylosin appears to be eliminated in an active form. Macrolide antibiotics and their metabolites are excreted 
mainly in bile (>60%) and often undergo enterohepatic cycling. Urinary clearance may be slow and variable (often 
<10%) but may represent a more significant route of elimination after parenteral administration [44]. 
PG data. According to “rule of 5” by Lipinski et al. [45], macrolide antibiotics azithromycin and clarithromycin are 
predicted to have poor permeation or absorption because of their large molecular weight and hydrogen binding 
potential; however, these macrolides show moderate to excellent oral exposure in preclinical species and humans [34]. 
One study reported that the biliary and intestinal excretion of azithromycin in rats is mediated by P-gp and MRP2 [33]  
(Table 1). The possible involvement of P-gp in azithromycin disposition is confirmed by the study described by He et 
al. [46]; they found that PK of azytromycin may be influenced by SNPs in ABCB1 gene in healthy Chinese volunteers 
(Table 4). Garver et al. [34] found that the intestinal OATPs transporters are involved in the oral absorption of 
azithromycin and clarithromycin in the rat (Table 1). 
Oxazolidinones 
Among oxazolidinones agents linezolid is the first and the only oxazolidinone approved for therapeutic use by FDA. It 
is active against gram-positive bacteria, including penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant 
enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). It is used for the treatment of nosocomial 
pneumonia, uncomplicated and complicated skin and soft tissues infections caused by gram-positive bacteria [47]. 
Moreover, linezolid may be used in the treatment of multi-drug resistant tuberculosis, as second line agent.  
Mechanism of action. It acts by binding to the 50S subunit of the bacterial ribosome producing an early inhibition of 
protein synthesis [48].  
PK-PD parameters predictive of efficacy.  Linezolid shows a time dependent killing. Data from literature reported 
that PK/PD parameters predictive of linezolid efficacy against staphylococci and enterococci are AUC/MIC>100, 
%TMIC>85, Cmin≥2 mg/L and/or AUC>160–200 mg·h/L for [49, 50]. Potential overexposure was defined as Cmin>10 
mg/L and/or AUC>400 mg·h/L [49, 51]. Linezolid is bacteriostatic with a significant post-antibiotic effect against the 
key pathogens.  
ADME. Linezolid is available as intravenous formulation, film-coated tablets and oral suspension. The standard dose is 
600 mg every 12 h and no dose adjustment is needed when switching from the intravenous to oral formulations or when 
there is moderate renal or hepatic impairment [52]. There are few data of linezolid PK in special situations such as 
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ECMO [53]. Linezolid is well absorbed, with a bioavailability of approximately 100% in healthy volunteers. The level 
of plasma protein binding is 31% and the volume of distribution approximates to the total body water content of 40–50 
L. Linezolid is metabolized to two inactive metabolites, an aminoethoxyacetic acid (metabolite A) and a hydroxyethyl 
glycine (metabolite B). It is excreted by non-renal (65%) and renal mechanisms. Renal tubular reabsorption may occur. 
A proportion of the dose is excreted unchanged in the urine [52]. 
PG data. The only published study dealing with linezolid PG was reported by Gebhart et al. These authors postulated 
that rifampicin may stimulate induction of P-gp expression, leading to increased clearance of linezolid. They found a 
significant reduction in linezolid plasma levels when a critically ill patient was treated with intravenous linezolid and 
rifampicin respect to linezolid alone. Thus, this research supports the hypothesis that P-gp expression plays a role in the 
potential interaction between linezolid and rifampicin [54]. 
 
Fluoroquinolones  
Fluoroquinolones are broad spectrum antimicrobials developed synthetically from the quinolone class of antimicrobials 
[55]. Ciprofloxacin exhibits activity against  gram-negative and atypical organisms (Mycoplasma pneumoniae,  
Chlamydia pneumoniae, Legionella  pneumophila) but lack potent in vitro activity against Streptococcus pneumoniae. 
Second and third generation fluoroquinolones such as levofloxacin and moxifloxacin, closed this coverage gap, 
providing  enhanced bactericidal activity against  gram-positive organisms [56].  
Mechanism of action. Fluoroquinolones act by inhibiting two bacterial enzymes, DNA gyrase and topoisomerase IV, 
which have essential and distinct roles in DNA replication. Quinolones bind to the complex of each of these enzymes 
with DNA; the resulting complexes, including the drug, block progress of the DNA replication enzyme complex. 
Ultimately, this action results in damage to bacterial DNA and bacterial cell death [57]. 
PK-PD parameters predictive of efficacy. Fluoroquinolones exhibit concentration-dependent killing and a post-
antibiotic effect [58]. Overall, the AUC/MIC has had the greatest correlation with outcome in either in-vitro or animal 
models of infection [59], but the greatest debate has focused on the magnitude of the AUC/MIC needed to maximize 
outcome or prevent emergence of resistance. Limited data from studies of human infections are available for the 
purpose of evaluating the PD thresholds necessary for maximizing therapeutic success. Attempts at “one-size-fits-all” 
cutoff values or thresholds have been problematic and have lead to some pointed debate. While the best PK–PD targets 
to guide the use of fluoroquinolones may be unclear, the currently accepted target remains an AUC/MIC of ≥125 for 
gram-negative organisms [58].  
ADME. After oral administration fluoroquinolones are rapidly absorbed from the intestine and widely distributed 
throughout the body [60, 61]. The major route of fluoroquinolone elimination is renal excretion as only a small fraction 
was found to be eliminated through the bile. Metabolism accounts for the hepatic elimination of fluoroquinolones, and 
biliary excretion is usually a minor elimination pathway, except for moxifloxacin. Fluoroquinolone metabolic pathways 
include glucuronidation, N-oxidation and desmethylation [62]. PK data regarding the most commonly used 
fluroquinolones are reported in Table 2. 
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 1 
Fluoroquinolone 
Agent 
Protein           
Binding 
(%) 
Distibution 
Volume (L/kg) GI Absorption (%) Metabolism (%) 
Excretion (%) 
Renal Hepatobiliary 
Ciprofloxacin 20-40 - 70 - 40-50 (parent drug) - 
Levofloxacin 24-38 1.1 100 Limited by the liver 87 (parent drug) - 
Moxifloxacin 48 3.6 - 52% (N-sulfate and acyl glucuronide conjugates) 40 (parent drug and metabolites) 60 (parent drug and metabolites) 
Ofloxacin 32 - 98 Limited by the liver 65-80(parent drug) 4-8 in feces (parent drug) 
Gemifloxacin 60-70 1.6-12.1 71 Limited by the liver 36% (parent drug and metabolites) 60 (parent drug and metabolites) 
 2 
Table 2. PK data of fluoroquinolone compounds. GI, gastrointestinal.[60, 62, 63].  3 
 4 
 5 
 6 
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PG data. Since these antibacterial agents are zwitterionic compounds, a passive diffusion mechanism may not fully 1 
explain their high intestinal absorption, selective tissue distribution and selective excretion. Accordingly, involvement 2 
of membrane transporters has been proposed. In the last years many studies investigated the involvement of several 3 
transporters in fluoroquinolone bioavailability. Notwithstanding that all these studies were performed in-vitro, they 4 
could have important consequences in clinical practice for example in the field of drug-drug interactions. Moreover, for 5 
transporters coded by polymorphic gene the study of polymorphisms implicated in drug PK variability and response to 6 
treatment may be useful to improve outcome.   7 
In Table 3 specific transporters involved in fluoroquinolone bioavailability are reported. The influence of SNPs on gene 8 
coding for transporters has been only investigated for moxifloxacin. In particular Weiner et al. [64] found that the SNP 9 
3435C>T (rs1045642) in ABCB1 gene coding for P-gp have no influence on moxifloxacin PK values in patients. 10 
Therefore P-gp seems not to be involved in moxifloxacin disposition (Table 4). 11 
 12 
 13 
 14 
 15 
 16 
12 
 
 1 
Table 3. Specific transporters of fluoroquinolones and ADME processes involved. ADME, Absorption distribution metabolism elimination; P-gp, P-glycoprotein; MRP, 2 
multidrug resistance–associated protein; OATP, organic anion transporting polypeptide; BCRP, breast cancer resistance protein; ABC, ATP binding cassette; SLCO, solute 3 
carrier organic anion transporter; BBB, blood brain barrier.     4 
Fluoroquinolone    
Agent Transporter Coding gene Model ADME Process Involved Ref. 
Grepafloxacin P-gp ABCB1 Caco-2 Gastrointestinal secretion Yamaguchy et al. 2000 [65] 
Levofloxacin 
     
Levofloxacin P-gp ABCB1 LLC-PK1 Renal tubular secretion Ito et al. 1997 [66] 
Levofloxacin MRP2, P-gp ABCC2, ABCB1 Caco-2 and MDCK Transepitelial secretion Lowes et al. 2002 [67] 
Levofloxacin OATP1A2 SLCO1A2 Xenopus oocytes and Caco-2 Cellular uptake Maeda et al. 2007 [68] 
Ciprofloxacin 
     
Ciprofloxacin BCRP ABCG2 MDCK and mice Milk secretion/oral availability Merino et al. 2006 [69] 
Ofloxacin 
     
Ciprofloxacin BCRP ABCG2 MDCK Biliary excretion Ando et al. 2007 [70] 
Ofloxacin 
     
Ciprofloxacin MRP4 ABCC4 Murine macrophages Intracellular excretion Marquez et al. 2009 [71] 
Ciprofloxacin OATP1A5 SLCO1A5 Rat enterocytes and Xenopus oocytes Intestinal absorption Arakawa et al. 2012 [72] 
Ciprofloxacin BCRP ABCG2 MDCK, HEK 293 and Caco-2 Intestinal secretion Haslam et al. 2011 [73] 
     
Sparfloxacin P-gp ABCB1 LLC-PK1 BBB transport de Lange et al. 2000 [74] 
      
Sparfloxacin P-gp ABCB1 Caco-2 Intestinal elimination Cormet-BoyaKa et al. 1998 [75] 
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Antibiotic Transporter/          Enzyme 
Coding 
gene SNP investigated in-vivo effect Model Reference 
Macrolides 
      
Azytromycin P-pg ABCB1 
2677G>T Lower Cmax in patients with 2677TT/3435TT  
genotype, higher Tmax in patients with 
2677TT/3435TT genotype 
Healthy Chinese  volunteers, n=20 He et al. 2009 [46] 3435C>T 
1236C>T 
  
   
Fluoroquinolones  
   
Moxifloxacin P-pg ABCB1 3435C>T SNP 3435C>T do not influence moxifloxacin plasma levels Healthy volunteers, n=16 
Weiner et al. 2007 
[64] 
  
   
Beta-lactams 
   
Dicloxacillin P-pg ABCB1 3435C>T 
SNP 3435C>T do not influence dicloxacillin plasma 
levels, use of rifampicin increases dicloxacillin 
metabolism Healthy volunteers, n=18 
Putnam et al. 2005 
[76] 
       
Cloxacillin P-pg ABCB1 1236C>T Lower Cmax, AUC, and urinary excretion in subjects 
with 1236CC genotype 
Healthy Chinese male volunteers, n=18 Yin et al. 2009 [77] 
  
     
Lipopeptides 
      
Daptomycin P-pg ABCB1 3435C>T 
Higher Cmax in patients with 3435TT, 2677TT, and 
1236TT  genotype. Higher AUC in patients with 
3435TT genotype and lower clearance 
Caucasian patients, n=19 Baietto et al. 2012 [78] 
  
     
Sulfonamides 
Sulphamethoxazole CYP2C9 CYP2C9 
CYP2C9*2, 
CYP2C9Arg144 to Cys Subjetcs with homozygous mutate genotype for 
CYP2C9Arg144 to Cys  and CYP2C9Ile359 to Leu 
showed decrease in the activity of CYP2C9 
Human liver, n=26 Gill et al. 1999 [79] 
CYP2C9*3, 
CYP2C9Ile359 to Leu 
       
Sulphamethoxazole GCLC GCLC rs761142T > G rs761142 T > G influences sulphametoxazole induced hypersensitivity HIV patients, n= 171 and n=249 
Wang et al. 2012 
[80] 
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Table 4. Continued. 
     
Antibiotic Transporter/     Enzyme 
Coding 
gene SNP investigated in-vivo effect Model Reference 
Antituberculars 
    
Rifampicin 
OATP1B1 SLCO1B1 
463C>A,521T> 
C,1463G>C, 
388A>G,11187G>A Lower rifampicin exposure in patients with SLCO1B1 463CA 
genotype Patients, n=72 
Weiner et al. 2010 
[81]  
OATP1B3 SLCO1B3 334T>G 
P-pg ABCB1 3435C>T 
 
 
Rifampicin 
 
OATP1B1 SLCO1B1 463C>A,                                                            521T> C, 388A>G 
Lower rifampicin exposure in patients with SLCO1B1 463CA 
genotype Healthy volunteers, n=11 
Kwara et al. 2014 
[82] 
       
Rifampicin CES2 CES2 2263A>G, 2263A>G may alter rifampicin metabolism by affecting expression of the gene Korean patients, n=35 Song et al. 2013 [83] 
       
       
Rifampicin 
P-pg ABCB1 3435C>T, 2677G>T, 1236C>T, rs3842 
Patients heterozygous and homozygous for SLCO1B1 rs4149032 
polymorphism had low-level rifampin exposure African patients, n=60 Chigutsa et al. 2011 
[84] 
OATP1B1 SLCO1B1 521T>C, rs4149032, 463C>A 
PXR PXR 63396C>T, 44477T>C 
CAR CAR rs2307424 
Isoniazid NAT2 NAT2 
NAT2*5, 341T>C 
NAT2 genotype affects isoniazid plasma levels Patients, n=60 Parkin et al. 1997 [85] 
NAT2*6, 590G>A 
NAT2*7, 857G>A 
NAT2*12, 803A>G 
NAT2*13, 282C>T 
NAT2*14, 434A>C 
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Table 4. Continued. 
     
Antibiotic Transporter/          Enzyme 
Coding 
gene SNP investigated in-vivo effect Model Reference 
Isoniazid NAT2 NAT2 NAT2*5 
NAT2 genotype affects isoniazid PK variability Caucasian healthy 
volunteers, n=18 
Kinzig-Schippers et 
al. 2005 [86] NAT2*6 
NAT2*7 
Isoniazid NAT2 NAT2 NAT2 genotype affects the EBA of isoniazid over a range of doses African patients, n=87 Donald et al. 2004 [87] 
       
 1 
Table 4. PG  studies regarding association among antibiotic PK and genotype of transporters and enzymes involved in ADME processes. ADME, absorption distribution 2 
metabolism elimination; P-gp, P-glycoprotein; OAT, organic anion transporter; ABC, ATP binding cassette; SLC, solute carrier; CES, Carboxylesterase-2; PXR, pregnane X 3 
receptor; CAR, constitutive androstane receptor; NAT,  N-acetyltransferase; CYP, Cytochrome P450; GCLC, glutamate-cysteine ligase catalytic subunit. Rs number: ABCB1 4 
2677G>T, rs2032582; ABCB1 3435C>T, rs1045642; ABCB1 1236C>T, rs1128503; SLCO1B1 463C>A, rs11045819; SLCO1B1 521T> C, rs4149056; SLCO1B1 1463G>C, 5 
rs59502379; SLCO1B1 388A>G, rs2306283; SLCO1B111187G>A, rs4149015; SLCO1B3 334 T>G, rs4149117;SLCO1B1 463G>A, rs11045819; PXR  63396C>T, rs2472677; 6 
PXR  44477T>C, rs1523130; NAT2*5, 341C>T,  rs 1801280; NAT2*6, 590G>A, rs1799930; NAT2*7, 857G>A, rs1799931; NAT2*12, 803A>G, rs1208; NAT2*13, 282C>T, 7 
rs1041983. 8 
 9 
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β-lactam antibiotics 1 
β-lactam antibiotics are a broad class of antibiotics characterized by having a β-lactam ring in their molecular structures. 2 
This class includes penicillin derivatives, cephalosporins, monobactams, and carbapenems. β-lactam antibiotics are 3 
administered for the prophylaxis and treatment of bacterial infections caused by susceptible organisms. They are active 4 
against a wide variety of gram-positive and gram-negative bacteria, including anaerobes. 5 
Mechanism of action. Most β-lactam antibiotics work by inhibiting cell wall biosynthesis in the bacterial organism and 6 
are the most widely used group of antibiotics. β-lactams are bactericidal, and act by inhibiting the synthesis of the 7 
peptidoglycan layer of bacterial cell walls. 8 
PK-PD parameters predictive of efficacy. The PK/PD index that best describes efficacy for β-lactam agents is the 9 
time the free drug concentration remains above MIC (f T>MIC) [88]. However, the optimal f T>MIC is controversial. 10 
Targeting trough concentration (4-5xMIC) may decrease the likelihood of suboptimal plasma concentrations. The 11 
higher concentration would enable enhanced distribution of drug into tissues with deranged microcirculation (e.g., 12 
septic shock) and improve impaired tissue β-lactam penetration [89-91]. In the absence of well conducted, prospective, 13 
clinical trials addressing the therapeutic benefit of currently recommended PK-PD targets, 100% f T>MIC could be 14 
considered a prudent PK/PD target for β-lactams in  critically ill patients or immunocompromised. Non-critically ill and 15 
non-immunocompromised patients may only require minimal exposures of 40-70% f T>MIC [92]. 16 
ADME. Penicilins. Penicillins have different values of protein binding; with the exception of piperacillin and 17 
clavulanic acid that are not orally absorbed, the gastrointestinal absorption is >50% for almost all drugs considered. 18 
They are minimally metabolized and the main route of elimination is renal excretion as parent drug. PK characteristics 19 
of penicillins are reported in Table 5. 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
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Penicillins 
Protein 
Binding 
(%) 
Distibution 
Volume (L/kg)a 
GI       
absorption    
(%) 
Metabolism (%) Excretion (%) 
Renal Hepatobiliary 
Penicillin G 20-30 0.17-0.21 50 20 60 (parent drug) 
Cloxacillin [77, 93] 
 
>90 na 37-60 22 (hydrolysis) >90 
 
Dicloxacillin [94] 97 na 50 10 >90 (parent drug) 
 
       
Ampicillin [95-97] 28 0.32 80b 10 65 (parent drug) minimal 
Amoxicillin [98] 20 0.43 75 <30 >70 (parent drug) 
Piperacillin [99-103] 
 
30 0.23-0.27 no 
 
56-73 (parent drug) 
Clavulanic Acid 25 - no 55-75 - 
Sulbactam [95-97] 28 0.34 80b 10 46 (parent drug) minimal 
       
Tazobactam [99, 100] 20-23 0.18-0.27 50 
 
60 
 
a, value obtained considering a body weight of 70 kg 
b, after administration of sulfaticillin (ampicillin + sulbactam) 
 1 
Table 5. PK characteristics of penicillins. GI, gastrointestinal.  2 
 3 
ADME. Cephalosporins. Cephalosporins are a new class of broad-spectrum antibiotics that bind to plasma proteins in 4 
different degrees. Reported values for protein binding range from 6% for cephradine to 92% for cefazolin [104]. 5 
Cephalosporins generally distribute well into the lung, kidney, urine, synovial, pleural, and pericardial fluids. 6 
Penetration into the CSF of some third generation cephalosporins (cefotaxime, ceftriaxone, and ceftazidime) is adequate 7 
to effectively treat bacterial meningitis. Elimination is primarily via the kidneys, though a few exceptions include 8 
cefoperazone and ceftriaxone which have significant biliary elimination. Biliary excretion of cephalosporins is highly 9 
dependent on molecular weight in rats: less than 15% of the dose is excreted into the bile for cephalosporins with a 10 
molecular weight of less than 450, but those with a molecular weight of more than 450 exhibit 15 to 100% recovery in 11 
bile [105]. In addition, their elimination pathway is mainly excretion into bile and/or urine with minimal metabolism in 12 
the body [106, 107]. 13 
ADME. Carbapenems. Plasma protein binding of imipenem, meropenem and doripenem is low (20, 2 and 9% 14 
respectively) and independent of plasma drug concentrations [108]. Ertapenem is highly bound to plasma protein, from 15 
~95% at concentrations of 50 mg/L to ~92% at concentrations of 150 mg/L [109]. Carbapenems are not orally absorbed, 16 
therefore they are administered via infusion.  PK characteristics of carbapenems are reported in Table 6. 17 
 18 
 19 
 20 
 21 
 22 
 23 
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Carbapenems 
Protein 
binding 
(%) 
Distibution       
Volume               
(L/kg) 
Metabolism (%) 
Excretion (%) 
Renal Hepatobiliary 
Imipenem [110] 20 0.20-0.23 - 70 (parent drug) 
 
Meropenem 
[111, 112] 2 0.18-0.30 
19-27 (chemical hydrolysis, 
extrarenal metabolism, 
and renal metabolism via DHP-I 
70 (parent drug) 
 
Doripenem 
[113, 114] 9 0.24 no  97.2 (parent drug)  
Ertapenem [109, 
115] 95-92 
0.11-0.12 (total   
fraction) minimal ~40 (parent drug) 10 (parent drug) 
a, value obtained considering a body weight of 70 kg 1 
Table 6. PK characteristics of carbapenems. 2 
  3 
PG data. As above reported β-lactam agents are primarily excreted by the kidneys and are poorly metabolized. From 4 
1995 many studies, especially on cephalosporins, investigated transporters responsible of β-lactam bioavailability 5 
(Table 7). Uptake transporters as peptide transporter 1 and 2 (PEPT1, PEPT2) were found to be involved in intestinal 6 
and renal absorption of cephalosporins [116-118]. Moreover cephalosporins showed interaction with the organic anion 7 
tranporters 1, 3, and 4 (OAT1, OAT3, OAT4) localized in the proximal tubule where they play a distinct role in the 8 
basolateral and apical uptake of cephalosporin antibiotics [119-121]. Recently, Kato et al. [122] found that weight-9 
dependent biliary excretion of several cephalosporins including cefoperazone, cefbuperazone, cefpiramide, all of which 10 
are mainly excreted into bile, is mediated by MRP2 transporter. The involvement of P-gp on β-lactam disposition was 11 
only investigated for dicloxacillin and cloxacillin [77, 123]. The influence of SNPs in gene coding for transporters 12 
involved in β-lactam bioavailability was poorly studied. Putnam et al. [76] found that 3435C>T (rs1045642) variant of 13 
the ABCB1 do not influence dicloxacillin plasma levels in 18 volunteers but the data suggested that rifampicin induces 14 
intestinal P-gp and increases dicloxacillin metabolism. Yin et al. [77] found that the 1236C>T (rs1128503) variant of 15 
ABCB1 appeared to be an important contributor to inter-individual differences in plasma cloxacillin exposure in healthy 16 
Chinese male subjects. This effect depends most likely through an effect on oral absorption rather than on disposition 17 
(Table 4). 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
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Beta-lactams agents Transporter Coding gene Model ADME Process Involved Ref. 
Dicloxacillin P-pg ABCB1 MDCK Renal clearance Susanto et al. 2002 [123] 
      
Ceftriaxone 
MRP2 ABCC2 
 
Biliary excretion Kato et al. 2008 [122] 
Cefoperazone 
Cefbuperazone 
Cefpiramide 
     
Cefaloridine 
OAT3 
 
HEK293 cells Renal secretion Ueo et al. 2005 [119] Cefdinir SLC22A8 
Cefotiam 
 
      
Cefaloridine OAT1 SLC22A6 Xenopus laevis oocytes Renal secretion Jariyawat et al. 1999 [120] 
      
Cefazolin 
OAT1 
 
Xenopus laevis oocytes Renal secretion Uway et al. 2002 [121] Cefotiam SLC22A6 
Cephalexin 
 
      
Cephalexin 
PEPT2 SLC15A2 SKPT cells Renal reabsorption Luckner et al. 2004 [124] 
Cefadroxil 
Cefaclor 
Cyclacillin 
Cephradine 
Moxalactam 
      
Ceftibutene 
PEPT1 SLC15A1 Caco-2 cells Intestinal absorption Matzumoto et al. 1994 [116] Cephradine 
      
Ceftibutene 
PEPT1 SLC15A1 Xenopus  oocytes Intestinal and renal 
absorption Saito et al. 1995 [117] Cephradine 
      
Ceftibutene 
PEPT1 SLC15A1 LLC-PK1 Intestinal absorption Terada et al. 1997 [118] 
Cephradine 
 1 
Table 7. Specific transporters of cephalosporins and type of ADME processes involved. ADME, absorption distribution 2 
metabolism elimination; P-gp, P-glycoprotein; MRP, multidrug resistance–associated protein; OAT, organic anion 3 
transporter; PEPT, peptide transporter;  ABC, ATP binding cassette; SLC, solute carrier.     4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
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Daptomycin 1 
Daptomycin is a lipopeptide antibiotic used for the treatment of complicated skin and soft-tissue infections, right-sided 2 
infective endocarditis due to Staphylococcus aureus, S. aureus bacteraemia when associated with right-sided infective 3 
endocarditis or with complicated skin and soft-tissue infections. It is active against gram-positive bacteria only [125].   4 
Mechanism of action. Daptomycin is rapidly bactericidal. It acts by penetrating into the membrane of gram-positive 5 
bacteria and causing rapid membrane depolarization [126]. 6 
PK-PD parameters predictive of efficacy. Daptomycin has a concentration-dependent bactericidal activity in-vitro 7 
and in-vivo animal models. The PK/PD indices that best correlate with its activity are Cmax/MIC or AUC/MIC. Optimal 8 
theoretical PK/PD determinants correlated with improved outcome and reduced toxicity are Cmax >60 mg/L [127] and 9 
Cmin<24.3 mg/L [128], respectively for infections sustained by microorganisms having MIC<1 mg/L. 10 
ADME. Animal studies showed that daptomycin is not absorbed to any significant extent after oral administration. The 11 
volume of distribution at steady state of daptomycin in healthy adult subjects was approximately 0.1 L/kg 12 
corresponding with a predominantly extracellular distribution and high protein binding [129]. In healthy volunteers and 13 
patients treated with daptomycin, protein binding averaged about 90% including subjects with renal impairment. The 14 
binding is reversible and concentration indipendent [125, 130]. Tissue distribution studies in rats showed that 15 
daptomycin appears to only minimally penetrate the BBB and the placental barrier following single and multiple doses. 16 
Daptomycin is mainly excreted by the kidneys. In patients with severe or terminal renal insufficiency (creatinine CL< 17 
30 ml/min) and in subjects undergoing hemodialysis or peritoneal dialysis daptomycin should be used cautiously 18 
because elimination half-life and AUC are increased by two- to three-fold [131]. In in-vitro studies, daptomycin was not 19 
metabolized by human liver microsomes with only minimal involvement of the CYP P450 isoenzymes [129]. 78% of 20 
the administered dose was recovered from the urine based on total radioactivity, whilst urinary recovery of unchanged 21 
daptomycin was approximately 50% of the dose. About 5% of the administered radiolabeled dose is excreted in the 22 
feces [125].  23 
PG data. In a recent study conducted by Lemaire et al. [35] it was reported that daptomycin is subjected to efflux from 24 
THP-1 macrophages and MDCK cells by P-gp, which reduces its intracellular activity against phagocytized 25 
Staphylococcus aureus (Table 1). The influence of SNPs on ABCB1 gene coding for P-gp on daptomycin bioavailability 26 
was observed by Baietto L et al.  [78]. They found that patients with homozygous mutate genotype (TT) for 3435C>T 27 
(rs1045642), 1236C>T (rs1128503) and 2677G>T (rs2032582) had significantly higher levels of daptomycin plasma 28 
levels and reduced clearance. These results highlight the importance of P-gp in understanding inter-individual 29 
variability of daptomycin PK (Table 4).  30 
 31 
Glycopeptides: Vancomycin and Teicoplanin 32 
Glycopeptide antibiotics are a class of antibiotic drugs active against gram-positive bacteria. They are characterized by 33 
a narrow spectrum of action, and are active against staphylococci (including methicillin resistant strains), streptococci, 34 
enterococci and Clostridium spp. Tissue diffusion is not generally good, as into  the cerebrospinal fluid, for example. 35 
Penetration can be influenced by inflammation and disease state. 36 
Mechanism of action. They inhibit the synthesis of cell walls in susceptible microbes by inhibiting peptidoglycan 37 
synthesis. They bind to the aminoacids within the cell wall preventing the addition of new units to the peptidoglycan.  38 
PK-PD parameters predictive of efficacy. Vancomycin and teicoplanin have a time dependent activity and 39 
vancomycin has clear dose–response correlations, since highly significant association between clinical cure and an 40 
AUC/MIC>400 was demonstrated [132]. Based on this study, current dosing guidelines propose target trough levels of 41 
21 
 
15–20 mg/L for a pathogen with an MIC of 1 mg/L to obtain the target AUC/MIC [133]. The dose-toxicity relationship 1 
remains to be established [134]. TDM of vancomycin is frequently employed especially in patients with impairment of 2 
renal function. Some authors suggested a specific role for continuous infusion to increase the likelihood of 3 
AUC/MIC>400 [135]. 4 
Teicoplanin acts in a time dependent manner: trough concentrations >10 mg/L have been recommended for most 5 
infections and >20 mg/L for endocarditis [136].  6 
ADME. Vancomycin protein binding is low, a level of 50–55% is most often stated [137, 138]. Volume of distribution 7 
is around 0.4 L/Kg. Teicoplanin is characterized by a high protein binding of 90% and a volume of distribution of 1 8 
L/kg [139]. Both vancomycin and teicoplanin are cleared unchanged renally, and doses should be reduced in patients 9 
with renal impairment.  10 
PG data. To date, no data were published about PG of vancomycin and teicoplanin. As vancomycin induced kidney 11 
damage is determined via the tubular secretion [140], in the future, investigating the influence of SNPs in genes coding 12 
for proteins involved in renal transporters activity, as P-gp, OCT, and OAT, could be useful to further individualize 13 
therapy. Del Moral et al. [141] reported that P-gp is thought to be involved in the defense against cyclosporin 14 
nephrotoxicity. Considering these data, studying the influence of P-gp in vancomycin elimination could be useful to 15 
reduce the drug induced kidney damage.  16 
 17 
Polymixins: Colistin and polymixin B 18 
Colistin and polymixin B are old antibiotics which had fallen out of favour in the 1970s due to reports of nephrotoxicity 19 
and neurotoxicity [142]. In 1980s due to increased emergence of bacterial resistance and declining development of new 20 
antibiotics, colistin had to be used against multi drug resistant bacteria.. We will focus on colistin, as an example of this 21 
class of antibiotics. Colistin is a cationic antimicrobial peptide available in two different forms: colistin sulphate and  22 
sodium colistin methanesulphonate (CMS). CMS is ‘less toxic’ than colistin when administered parenterally [143] and 23 
hence it is CMS that is present in all parenteral (and most inhalational) formulations. Colistin is used for the treatment 24 
of infections caused by gram-negative bacilli, including multidrug-resistant Pseudomonas aeruginosa, Acinetobacter 25 
baumannii and Klebsiella pneumoniae [144].  26 
Mechanism of action. Colistin is an amphipathic compound. Hydrophobic/hydrophillic regions interact with the 27 
cytoplasmic membrane like a detergent, solubilizing the membrane in an aqueous environment.  28 
PK-PD parameters predictive of efficacy. Colistin has a concentration dependent activity. Recently it was revealed 29 
that CMS is an inactive pro-drug of colistin, therefore showing separate determination of CMS and formed colistin 30 
concentrations are essential to fully understand the pharmacology of CMS/colistin [145] and to optimize the outcome in 31 
clinical practice. In clinical practice the attainment of steady-state plasma colistin concentrations above the MIC 32 
breakpoint of 2 mg/L was found to be associated with improved outcome [146-148].   33 
ADME. Both colistin sulfate and CMS are administered intravenously and colistin sulfate is also available as topical 34 
formulation for skin infections. Colistin is not absorbed from the gastrointestinal tract [149]. Following an intravenous 35 
bolus dose of colistin sulfate only 0.18 ± 0.14% of the total colistin dose is recovered in urine over 24 h [150]. 36 
Therefore this result suggested that colistin undergoes very extensive renal tubular reabsorption through a carrier-37 
mediated process, and that it is cleared mainly via nonrenal pathway [151]. After administration of CMS, colistin 38 
appears rapidly in plasma  [152]. PK analysis revealed that only approximately 7% of the administered dose of CMS 39 
was converted to colistin systemically. CMS is eliminated predominantly by the kidneys. After parenteral 40 
administration, approximately 60% of CMS is excreted in the urine during the first 24 h [152].  41 
22 
 
PG data. Given that one of the side effects associated with colistin treatment is neurotoxicity [153], and that colistin 1 
exhibits some of the characteristics possessed by known P-gp substrates [154],  Jin et al. [155] investigated whether 2 
efflux by P-gp was also contributing to the low brain uptake of colistin. These studies suggested that P-gp does not 3 
contribute to the low brain up-take of colistin and that the brain uptake of colistin is significantly increased during 4 
systemic inflammation when BBB integrity is compromised. 5 
 6 
Sulfonamides   7 
Sulfonamides were the forerunner of the modern era of antibiotis after discovery of sulfamidochrysoidine in 1935.  8 
The combination of adverse effects and bacterial resistance lead to a decrease in sulfonamides prescription, but their 9 
potential activity against parasitic infections revived the interests in these class of antibiotics. Since 1968, sulfonamides 10 
have been one of the components in combination with dihydrofolate reductase (DHFR) inhibitors, such as trimethoprim 11 
(co-trimoxazole; TMP-SMX). 12 
Sulfonamides are classified in short or intermediate acting (sulfisoxazole, sulfamethoxazole, sulfadiazine; these 13 
compound can also be used in combination ) and long-acting (sulfadoxine and sulfamethoxine).  14 
They are active against S.aureus, including MRSA, streptococci, E. faecalis, Corynebacterium diphteriae, Nocardia 15 
and Actinomyces as well as the majority of enteric gram negative bacteria. Combination of proguanil and certain 16 
sulfonamides are used in malaria due to P. falciparum. TMP- SMX has also activity against selected protozoa and  it is 17 
approved for the treatment of  Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment [156]. 18 
Mechanism of action.  Sulfonamides act by inhibiting the formation of dihydropteroic acid by competing with para-19 
aminobenzoic acid for condensation with 7,8-pterin pyrophosphate, a reaction catalyzed by the enzyme  dihydropteroate 20 
synthase (DHPS). Inihibition results in the cells becoming depleted of thetrahydrofolate [156].  21 
PK-PD parameters predictive of efficacy. Sulfonamides are generally bacteriostatic, no PK-PD parameters predictive 22 
of efficacy  or toxicity have been identified.  23 
ADME. Sulfonamides are administered orally or parenterally (sulfadiazine) and they are well absorbed by 24 
gastrointestinal tract. Half life ranges from 10 to 150 hours, according to different compounds.  They have a well 25 
distribution in CSF, pleural and peritoneal fluid as well as placental barrier.  Protein binding is high (50 to 95%). The 26 
major route of sulfonamides metabolism is liver, where they were acetylated and glucuronidated, whilst elimination is 27 
act by glomerular filtration.  28 
PG data. The majority of PG data available are focused on sulphamethoxazole. Sulphamethoxazole undergoes 29 
bioactivation to a hydroxylamine by CYP2C9 enzyme. In a study performed by Gill et al., it was observed that 30 
CYP2C9*2 and CYP2C9*3 polymorphisms may have some influence on the bioactivation of sulphamethoxazole, 31 
particularly in individuals who are homozygous mutants, and this could act as a protective factor against 32 
sulphamethoxazole hypersensitivity [79].  33 
Pirmohamed et al. investigated the influence of SNPs in gene coding for enzymes involved in co-trimoxazole 34 
metabolism in HIV-positive patients. They found that none of the SNPs investigated in CYP2C9, GSTM1, GSTT1, 35 
GSTP1 and NAT2 coding genes resulted major predisposing factors in determining individual susceptibility to co-36 
trimoxazole hypersensitivity in HIV positive patients [157]. A study performed by Wang et al. showed that SNP in 37 
glutamate cysteine ligase catalytic subunit coding gene (GCLC) (SNP rs761142 T>G)  was significantly associated with 38 
sulphamethoxazole -induced hypersensivity and with reduced GCLC mRNA expression in HIV infected patients [80] 39 
(Table 4). Susanto et al. found that sulphametoxazole is not a P-gp substrate [123].  40 
 41 
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First line antituberculars 1 
Antituberculars agents used as first line treatment are: isoniazid, rifampicin, , ethambutol and pyrazinamide. They are 2 
used in the treatment of susceptible mycobacterium tuberculosis. The treatment consists in the combination of the four 3 
drugs during the first two months of therapy and of isoniazid and rifampicin for the remaining four months.  4 
Mechanism of action. Isoniazid and ethambutol act by inhibiting mycobacterial cell wall lipid, and nucleic acid 5 
synthesis [158]. Rifampicin blocks transcription [158] while mode of action of pyrazinamide is poorly understood; it 6 
probably acts by disrupting membrane energetics and inhibiting membrane transport function in Mycobacterium 7 
tuberculosis [159].  8 
PK-PD parameters predictive of efficacy. No precise TDM targets are available from human studies. Targets plasma 9 
levels refers to findings in healthy volunteers. The following target ranges of peak plasma concentrations (2 hours post-10 
dose) have been proposed by Peloquin et al. [160]: 3-6 mg/L for isoniazid 300 mg qd, 8-24 mg/L for rifampicin 600 mg 11 
qd, 2-6 mg/L for ethambutol 25 mg/kg qd and 20-50 mg/L for pyrazinamide 25 mg/kg qd. To date, no toxicity targets 12 
have been proposed.  13 
ADME. Food reduces absorption of isoniazid, rifampicin and ethambutol; no effect on pyrazinamide oral biovailability 14 
was observed [161]. Thus isoniazid, rifampicin, and ethambutol should be given in an empty stomach [160]. Isoniazide 15 
is metabolized in the liver to acetylisoniazid via N-acetyltransferase (NAT2) enzyme, following, acetylisoniazid is 16 
hydrolized to acetylhydrazine that is further hydrolyzed to hepatotoxic compounds by cytochrome P450 2E1 (CYP2E1). 17 
Among antituberculars, isoniazid is the main drug to induce hepatotoxicity [162]. Rifampycin is metabolized to 25-18 
desacetyl rifampicin (it has 20% of microbiological activity that of the parent compound) by liver microsomes [163] 19 
and it is excreted via biliary and renal route [164]. Pyrazinamide is metabolized by the liver to pyrazinoic acid, 5-20 
hydroxy-pyrazinamide, 5-hydroxy-pyrazinoic acid and pyrazinuric acid and excretion is via renal route. Ethambutol is 21 
metabolized by the liver, approximately 50% and 20% of the initial dose is excreted unchanged in the urine, and in the 22 
feces, respectively [165].  23 
PG Data. Even if PG data regarding antituberculars were reported in a previous published review written by 24 
Ramachandran et al. [166], we have chosen to report all studies published until today in order to have a more clear and 25 
updated overview of antitubercular PG. Data are reported in Tables 4 and 8. Considering antituberculars PK, several 26 
studies investigated the influence of SNPs in SLCO1B1, ABCB1, CES2, PXR, CAR, NAT2 coding gene and 27 
antitubercular PK. In particular it was found that SLO1B1 463 CA genotype (rs11045819) and SLOCO1B1 rs4149032 28 
are associated to rifampicin plasma levels [81, 82, 84] (Table 4).   The most common side effect associated to first line 29 
antituberculars is hepatitis [167]. In Table 8 we reported previous published studies regarding the association among 30 
genotype of antitubercular transporters and metabolizing enzymes and toxicity. Several studies investigated the 31 
association between NAT2 genotype and emergence of  drug induced hepatotoxicity [168-173]. NAT2 is coded by a 32 
highly polymorphic gene and variability in  its expression can affect drug levels. NAT2 genotype resulted also 33 
associated to isoniazide plasma levels [85], to isoniazide PK variability [86], and to the early bactericidal activity (EBA) 34 
of isoniazid [87]. The association between CYP2E1 genotype and hepatotoxicity was also previously investigated. It 35 
was observed that patients with homozygous wild type genotype (CYP2E1 c1/c1) had higher risk of hepatotoxicity 36 
[162, 169, 171, 174]. GST are a group of enzymes involved in solubilization and elimination of isoniazid toxic 37 
metabolites. Two recently published studies reported that hepatotoxicity is also associated to GSTM1 and GSTT1 38 
genotype [175, 176]. Kim et al. hypothesized that polymorphisms in tumor necrosis factor (TNFα) gene are associated 39 
with hepatitis and they found an influence of TNFα 308G>A (rs1800629) on anti-tuberculosis drug induced hepatitis 40 
24 
 
[177]. The same authors found that SNPs in gene coding for P-gp, OATP1, and MRP2 were not associated to hepatitis 1 
induced by antituberculosis drugs in Korean patients [178].  2 
 3 
 4 
 5 
 6 
 7 
 8 
25 
 
 1 
Antibiotic   
administered 
Transporter/                  
Enzyme Coding gene Alleles SNP in-vivo effect Model Reference 
        
Isoniazid,        
Rifampicin NAT2 NAT2 
NAT2*5 481C>T NAT2 genotype affects the incidence of 
isoniazid and rifampicin-induced 
hepatotoxicity 
Japanese patients, n=77 Ohno et al. 2000 [172] NAT2*6 590G>A 
NAT2*7 857G>A 
        
Isoniazid NAT2 NAT2 
NAT2*5 341T>C 
NAT2 genotype is associated to adverse drug 
reactions induced by isoniazid Japanese patients, n=102 
Hiratsuka et al. 2002 
[170] NAT2*6 590G>A 
   
NAT2*7 857G>A 
     
Isoniazid NAT2                    CYP2E1 
NAT2                     
CYP2E1 
NAT2*5 - 
NAT2 genotype affects the incidence of 
isoniazid induced hepatotoxicity Korean patients, n=132 Cho et al. 2007 [169] 
NAT2*6 - 
NAT2*7 - 
c1,c2 - 
 
Isoniazid NAT2                    
CYP2E1 
NAT2                     
CYP2E1 
NAT2*5 - 
NAT2 and CYP2E1 genotype affects the 
incidence  of ATDH Taiwanese patients, n=34 Lee et al. 2010 [171] 
Rifampicin NAT2*6 - 
  
NAT2*7 - 
  c1,c2 - 
 
 NAT2 NAT2 NAT2*5 481C>T 
NAT2 genotype affects the incidence of 
isoniazid induced hepatotoxicity Tunisian patients, n=66 
Ben Mahmoud et al. 
2012 [168] 
Isoniazid 
 
  
NAT2*6 590G>A 
  
NAT2*7 857G>A 
 
Isoniazid NAT2 NAT2 - - NAT2 genotype affects the incidence of ATDH 474 cases, 1446 controls Wang et al. 2012 [173] 
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Table 8. Continued. 
      
Antibiotic 
administered 
Transporter/  
Enzyme Coding gene Alleles SNP in-vivo effect Model Reference 
Isoniazid 
CYP2E1 CYP2E1 c1,c2 - 
Patients with homozygous wild genotype 
CYP2E1c1/c1 had a higher risk of 
hepatotoxicity. 
Indian pediatric patients, n= 111 Roy et al. 2006 [174] Rifampicin 
Ethambutol 
Pyrazinamide 
 
Isoniazid MnSOD MnSOD 47C>T MnSOD and GSTM1 genotypes affect the 
incidence drug-induced liver injury (DILI) . 
Patients with MnSOD CC genotype and with 
GSTM1 null genotype are at increased risk to 
have DILI. 
Taiwanese patients, n=115 Huang et al. 2007 [176] Rifampicin 
NQO1 NQO1 609C>T 
Etambutol GST GSTM1, GSTT1 - - 
Pyrazinamide 
 
  
 
Isoniazid 
GST GSTM1, GSTT1 - - GSTM1 and GSTT1 genotypes affect the incidence of ATDH 
Indian patients, 50 cases, 246 
controls Gupta et al. 2013 [175] 
Rifampicin 
Etambutol 
Pyrazinamide 
 
Isoniazid 
TNF-α TNF-α - 308G>A 
Higher number of patients with ATD-induced 
hepatitis  had 308AG or 308AA genotypes 
compared with ATD-tolerant controls 
Korean ATD-induced 
hepatitis patients, n=77, Korean 
ATD-tolerant control,  n=229 
Kim et al. 2011 [177] Rifampicin 
Ethambutol 
Pyrazinamide 
 
Isoniazid 
Pgp                               
OATP1                           
MRP2 
ABCB1                       
SLCO1B1                            
ABCC2 
- - 
SNPs in gene coding for P-gp, OATP1, and 
MRP2 were not associated to hepatitis 
induced by antituberculosis drugs 
Korean patients, n=67 Kim et al. 2012 [178] Rifampicin 
Ethambutol 
Pyrazinamide 
27 
 
Table 8. PG studies regarding association among first line antituberculars associated toxicity and genotype of transporters and enzymes involved in ADME processes. ADME, 1 
absorption distribution metabolism elimination; NAT,  N-acetyltransferase; CYP, Cytochrome P450; Mn SOD, Manganese superoxide dismutase; NQO1, NAD (P) H Quinone 2 
oxidoreductase 1; GST, glutathione S-transferase; TNF, tumor necrosis factor; P-gp, P-glycoprotein; OAT, organic anion transporter; MRP, multidrug resistance-associated 3 
protein; ABC, ATP binding cassette; SLC, solute carrier. Rs number: NAT2*5, 481C>T, rs1799929; NAT2*6 590G>A,  rs1799930; NAT2*7, 857G>A, rs1799931; NAT2*5, 4 
341C>T,  rs1801280;  MnSOD 47C>T, rs4880; NQO1 609C>T, rs 1800566; TNF-α 308G>A, rs1800629. 5 
 6 
 7 
 8 
  9 
 10 
28 
 
Conclusions 1 
In the last years the antibiotic resistance is increased and the research on new compounds has decreased. TDM and PG 2 
represent two new strategies to individualize therapy in an era of enhanced complexity of patients and treatments, to 3 
increase the likelihood of appropriate therapy. The optimization of the plasma and tissue concentrations of antibiotics  is 4 
crucial especially in critically ill and immunocompromised patients. In this review we focused on describing PK of 5 
antibiotics and reporting PG studies to better understand the role of PG in improving treatment outcome. Regarding 6 
antituberculosis treatment, several studies showed that PG plays an important role especially in isoniazid metabolism. 7 
Considering the other antibiotics, most of the PG studies were mainly focused on drug transporters involved in drug 8 
elimination and distribution and data regarding the association between SNPs and clinical effect are still lacking.  9 
P-gp resulted the most studied transporter probably because it has a ubiquitary expression, it is coded by a polymorphic 10 
gene, and because several SNPs in ABCB1 gene are correlated with P-gp activity. As reported in this review, P-gp 11 
seems to have an influence on disposition of several antibiotics. P-gp is involved in transport of tobramycin, 12 
azithromycin and clarithromycin through the gut and it can potentially restrict intestinal absorption [25, 33, 179]. At the 13 
BBB level, P-gp was found to act as an efflux transporter for minocycline [32] and sparfloxacin [74]. P-gp is also 14 
involved in fluoroquinolone secretion at different compartments: gastrointestinal [65, 73, 75], renal [66], hepatic [70], 15 
transepithelial [67]. This efflux transporter is also important in PG because many drugs, as minocycline, are P-gp 16 
inhibitors. Minocycline, for example, was found to increase plasma levels of riluzole, and for this reason it is considered 17 
an antibiotic with anti-neurodegenerative properties [32]. β-lactams are substrate of uptake transporters as OAT and 18 
PEPT that mediate renal and intestinal absorption. To date, no SNPs in gene coding for these transporters have been 19 
identified. But, knowing the association between transporters and antibiotics could be useful both during drug 20 
development both in clinical practice when several drugs are co-administered.  21 
Notwithstanding antibiotic therapy is shorter than antiretroviral therapy, improving research on identification of SNPs 22 
involved in antibiotic bioavailability could be useful to understand the importance of a PG approach in clinical practice. 23 
In this review we reported data regarding PK, PDs, and PG of antibiotics to underline the importance of an integrated 24 
approach to individualize therapy. We acknowledge that in the last years PK/PD indexes, predictive of efficacy and 25 
toxicity, have been identified for almost all antibiotics and the use of TDM in clinical practice is increasingly 26 
recognized as a tool to optimize treatment.  27 
A new approach based on TDM and PG could be useful to further optimize therapy and perhaps to reduce costs 28 
associated to patients hospitalization. Further studies are needed to investigate new correlations among PG and drug 29 
bioavailability and to understand the full potential of  this innovative approach.   30 
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